EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity

Benedict J Panizza iD, Stephen John O'Leary iD, Christopher David Hart iD, Chandra Sai Diwakarla iD, Catherine Barnett iD, Pablo Lapuerta iD, John Lee, Shane Raines iD, Tera Quigley, Heather M Wolff, John Keilty iD, Rahul Ladwa iD und 5 weitere

Journal of Clinical Oncology · 2025-07 · 43 (19) · 2155-2163

DOI: 10.1200/jco.24.00905 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025-07. Verfasst von Benedict J Panizza und 16 weiteren Autor:innen. Beteiligte Einrichtung: Princess Alexandra Hospital, Brisbane, Australia. Hauptthemen laut MEDLINE: Cisplatin, Ototoxicity, Antineoplastic Agents, Thiosulfates. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This study evaluated DB-020, a formulation of thiosulfate for intratympanic (IT) injection, in patients receiving high-dose cisplatin chemotherapy. METHODS This randomized phase Ib clinical trial enrolled patients older than 18 years from five centers in Australia and the United States scheduled for at least three cycles of cisplatin and total cumulative exposure of ≥280 mg/m 2 . Patients received IT DB-020 (at a dose level of either 12% or 25%) in one ear and placebo in the other, once every 3 or 4 weeks, within 3 hours before receiving cisplatin. The primary end points were safety and tolerability, and the secondary end points included ototoxicity measured by air conduction audiometry. Ototoxicity was defined by American Speech-Language-Hearing Association criteria. RESULTS Twenty-two patients with a median age of 55.1 years were randomly assigned and received a mean total cumulative cisplatin dose of 255 mg/m 2 . Mean number of cisplatin cycles was 2.3. Twenty patients had both baseline and follow-up audiometry. Ear pain of short duration was common after IT injection. There were no persistent tympanic perforations and no serious adverse events in the category of ear and labyrinth disorders. A progressive reduction in patient numbers was observed at each cycle due to patients ceasing cisplatin treatment. DB-020 treatment did not affect plasma thiosulfate concentrations. Ototoxicity after cisplatin administration was significantly more common in placebo-treated ears than in DB-020–treated ears (DB-020 v placebo, P = .0027). The incidence of ototoxicity (250-8,000 Hz) was 85.0% in placebo-treated ears, and 54.5% and 22.2% in ears treated with DB-020 12% and DB-020 25%, respectively. CONCLUSION DB-020 IT injections were tolerated by patients and showed meaningful reductions in cisplatin ototoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinOtotoxicityAntineoplastic AgentsThiosulfatesHumansMiddle AgedFemaleMaleInjection, IntratympanicAdultAgedDouble-Blind Method

Substanzen

CisplatinAntineoplastic AgentsThiosulfatessodium thiosulfate

Autor:innen und Institutionen

  • Princess Alexandra Hospital, Brisbane, Australia.
  • University of Queensland, Brisbane, Australia.
  • The University of Melbourne, Melbourne, Australia.
  • St Vincent's Hospital Melbourne, Melbourne, Australia.
  • Fiona Stanley Hospital, Perth, Australia.
  • Lapuerta Consulting LLC, Skillman, NJ.

ORCID-Profile: Benedict J Panizza, Stephen John O'Leary, Christopher David Hart, Chandra Sai Diwakarla, Catherine Barnett, Pablo Lapuerta, Shane Raines, John Keilty, Rahul Ladwa, Margaret McGrath, Nagashree Seetharamu, Danny Rischin

Zitieren

APA

Panizza, B. J., O'Leary, S. J., Hart, C. D., Diwakarla, C. S., Barnett, C., Lapuerta, P., Lee, J., Raines, S., Quigley, T., Wolff, H. M., Keilty, J., Ladwa, R., Porceddu, S. V., McGrath, M., Seetharamu, N., Fua, T., & Rischin, D. (2025). Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity. Journal of Clinical Oncology, 43(19), 2155-2163. https://doi.org/10.1200/jco.24.00905

Vancouver

Panizza BJ, O'Leary SJ, Hart CD, Diwakarla CS, Barnett C, Lapuerta P, et al. Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity. Journal of Clinical Oncology. 2025;43(19):2155-2163. doi:10.1200/jco.24.00905

BibTeX
@article{Panizza2025,
  author = {Panizza, Benedict J and O'Leary, Stephen John and Hart, Christopher David and Diwakarla, Chandra Sai and Barnett, Catherine and Lapuerta, Pablo and Lee, John and Raines, Shane and Quigley, Tera and Wolff, Heather M and Keilty, John and Ladwa, Rahul and Porceddu, Sandro V and McGrath, Margaret and Seetharamu, Nagashree and Fua, Tsien and Rischin, Danny},
  title = {Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {19},
  pages = {2155--2163},
  doi = {10.1200/jco.24.00905}
}
Kostenlos starten →